Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
Sponsor: Centre Hospitalier Universitaire de Nice
This PHASE3 trial investigates Epidermolysis Bullosa and is currently ongoing. Centre Hospitalier Universitaire de Nice leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Universitaire de Nice
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Dijon, France
- • Montpellier, France
- • Nice, France
- • Toulouse, France